
News|Articles|October 31, 2026
Stool biomarker uncovers silent bowel disease in uveitis patients
Author(s)Sheryl Stevenson
A simple stool test may reveal hidden bowel disease in patients whose only symptoms are in their eyes.
Advertisement
Advertisement
Patients with idiopathic
Related to this article

Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.

The phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.

For Jeffrey S. Heier, MD, shaping retina trials, joining industry, and staying in clinic all rest on family and a strong team.

A hydrophilic topical cannabidiol formulation produced a sustained, largely local IOP reduction in DBA/2J mice with chronic dosing, adding a new wrinkle to one of glaucoma’s longest-running debates.

A longer axial length in the fellow eye of that treated for a rhegmatogenous retinal detachment was associated with a greater risk of a total retinal detachment.

Patricio G. Schlottmann, MD, Nicholas J. Volpe, MD, and Hunter Cherwek, MD, point to retinopathy follow-up, missed diagnoses, and low-resource care.
Advertisement
Advertisement


